MicroPort NeuroTech Limited (HK:2172)
:2172
Want to see HK:2172 full AI Analyst Report?
Top Page
MicroPort NeuroTech Limited
(2172)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$12.50
▲(10.62% Upside)
Action:ReiteratedDate:01/06/26
The score is driven primarily by strong profitability and growth indicators and a low-leverage balance sheet, partially offset by cash-flow concerns. Technicals are supportive but overbought conditions raise near-term risk, and valuation is relatively expensive with only a modest dividend yield.
Positive Factors
Recurring revenue model
A business model that mixes initial device sales with recurring consumables and maintenance creates durable revenue streams and higher customer lifetime value. Recurring revenue smooths cash flow, supports predictable install-base monetization and underpins long‑term margin resilience.
Negative Factors
Weak operating cash flow
Zero reported operating cash flow in the most recent period signals potential cash generation issues despite accounting profits. Poor OCF can limit the firm’s ability to self‑fund R&D, service working capital needs, or support consistent dividends and may require external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue model
A business model that mixes initial device sales with recurring consumables and maintenance creates durable revenue streams and higher customer lifetime value. Recurring revenue smooths cash flow, supports predictable install-base monetization and underpins long‑term margin resilience.
Read all positive factors
MicroPort NeuroTech Limited (2172) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.08B
Dividend Yield1.5%
Average Volume (3M)2.57M
Price to Earnings (P/E)31.0
Beta (1Y)0.88
Revenue Growth3.83%
EPS Growth-27.04%
CountryHK
Employees527
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.17
Shares Outstanding585,034,800
10 Day Avg. Volume2,683,063
30 Day Avg. Volume2,571,422
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.74
Price to Sales (P/S)6.15
P/FCF Ratio16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$12.50Price Target Upside10.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.54
Revenue Forecast (FY)HK$873.93M
MicroPort NeuroTech Limited Business Overview & Revenue Model
Company Description
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil ...
How the Company Makes Money
MicroPort NeuroTech Limited generates revenue primarily through the sale of its neurostimulation devices and related services. The company has a robust revenue model that includes direct sales to hospitals and healthcare providers, as well as part...
MicroPort NeuroTech Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 736.47M | 761.76M | 665.62M | 547.35M | 382.80M | 221.92M |
| Gross Profit | 541.92M | 555.93M | 511.79M | 393.00M | 298.35M | 164.78M |
| EBITDA | 295.56M | 340.48M | 221.60M | 175.46M | 108.83M | 68.24M |
| Net Income | 203.58M | 254.16M | 145.55M | -21.77M | 24.17M | 45.29M |
Balance Sheet | ||||||
| Total Assets | 2.08B | 2.04B | 1.96B | 1.82B | 1.34B | 785.61M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01B | 1.06B | 1.00B | 1.13B | 593.29M | 440.40M |
| Total Debt | 24.72M | 37.12M | 61.36M | 85.24M | 109.70M | 331.15M |
| Total Liabilities | 352.39M | 335.70M | 322.39M | 331.35M | 1.52B | 412.73M |
| Stockholders Equity | 1.73B | 1.71B | 1.64B | 1.47B | -174.94M | 372.88M |
Cash Flow | ||||||
| Free Cash Flow | 178.02M | 275.54M | -48.83M | 175.85M | 99.43M | 13.09M |
| Operating Cash Flow | 183.06M | 284.41M | 153.78M | 223.80M | 157.41M | 47.23M |
| Investing Cash Flow | -73.53M | -160.55M | -233.16M | -344.52M | -186.79M | -73.04M |
| Financing Cash Flow | -229.48M | -226.25M | -33.28M | 329.54M | 200.75M | 431.88M |
MicroPort NeuroTech Limited Technical Analysis
Negative
11.30
Price Trends
11.23
Negative
11.29
Negative
12.15
Negative
Market Momentum
-0.02
Negative
48.18
Neutral
59.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2172, the sentiment is Negative. The current price of 11.3 is above the 20-day moving average (MA) of 10.90, above the 50-day MA of 11.23, and below the 200-day MA of 12.15, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 48.18 is Neutral, neither overbought nor oversold. The STOCH value of 59.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2172.
MicroPort NeuroTech Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$7.96B | 27.86 | 4.88% | 0.48% | 35.28% | 146.71% | |
71 Outperform | HK$7.71B | 19.30 | 9.39% | 1.88% | 29.94% | 119.16% | |
69 Neutral | HK$6.08B | 31.02 | 10.38% | 1.50% | 3.83% | -27.04% | |
68 Neutral | HK$9.16B | 42.52 | 4.02% | ― | 5.10% | -32.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$4.43B | -18.13 | -11.27% | ― | 16.35% | 9.43% | |
43 Neutral | HK$3.29B | -4.06 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2172
MicroPort NeuroTech Limited
10.34
0.07
0.68%
HK:9996
Peijia Medical Ltd.
6.38
1.26
24.61%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
22.60
4.49
24.76%
HK:1302
LifeTech Scientific Corporation
2.08
0.66
46.48%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
12.21
3.72
43.82%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.47
-2.03
-45.11%
MicroPort NeuroTech Limited Corporate Events
MicroPort NeuroScientific Sets Up Strategy and Commercialization Committees, Adds Veteran Executive to Board
Dec 29, 2025
MicroPort NeuroScientific Corporation has created a new Strategic Committee and Commercialization Committee, effective 29 December 2025, to steer its medium- and long-term development and sharpen execution in bringing its neurotechnology products ...
MicroPort NeuroScientific Updates Board Composition and Committee Roles
Dec 29, 2025
MicroPort NeuroScientific Corporation has published an updated list of its directors and detailed their respective roles across five key board committees, underscoring its governance and oversight framework. The announcement confirms the current b...
MicroPort NeuroTech Grants Share Options to Key BCI Researcher
Nov 20, 2025
MicroPort NeuroTech Limited has announced the grant of 500,000 share options to Dr. Will Zhang, the RD Senior Director of BCI Technologies and Chief Researcher at the Chaos Brain-Computer Research Institute. This move is part of the company’...
MicroPort NeuroTech Announces Board Changes to Enhance Leadership
Nov 14, 2025
MicroPort NeuroTech Limited has announced changes in its board of directors, with Dr. Chang Zhaohua and Mr. Sun Qingwei resigning from their roles as non-executive directors and chairman of the board to focus on other business endeavors. Dr. Zhang...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.